.avif)
.avif)
Uniqure Email Format
Biotechnology Research
・
51-200 employees
・
Amsterdam, Netherlands
Uniqure is a biotechnology company that develops gene therapies to deliver potentially curative single treatments for patients with severe genetic diseases.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@uniqure.com
Company Overview
Industry
Biotechnology Research
Founded
1998
Headquarters
Amsterdam, Netherlands
Revenue
$25M-$50M
FUNDING Stage
Public
Website
Key Executives
Matt Kapusta (Chief Executive Officer), Christian Klemt (Chief Financial Officer), Amin Abujoub (Chief Technical Operations Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Uniqure?
Uniqure uses the firstinitiallast format on uniqure.com, so Jane Smith would be jsmith@uniqure.com.
What therapeutic areas does Uniqure focus on in its gene therapy pipeline?
Uniqure's pipeline targets Huntington's disease, hemophilia B, Fabry disease, ALS (SOD1), and temporal lobe epilepsy, all using its proprietary AAV-based gene therapy platform focused on liver-directed and central nervous system disorders.
How can I find the right contact at Uniqure for a research or partnership inquiry?
Using a tool like Clay can help you quickly identify and verify the right Uniqure contact for research or partnership outreach, whether you need someone in business development, clinical operations, or another team.
What is the status of Uniqure's AMT-130 program for Huntington's disease?
AMT-130 is Uniqure's investigational gene therapy for Huntington's disease and the first one-time administered gene therapy to enter clinical testing for the condition. In September 2025, Uniqure announced positive topline results from its pivotal Phase I/II study showing statistically significant slowing of disease progression.
Does Uniqure have a commercial partnership for its hemophilia B gene therapy?
Yes, Uniqure granted CSL Behring exclusive global commercialization rights to etranacogene dezaparvovec, its hemophilia B gene therapy, which received FDA approval and is marketed as HEMGENIX by CSL Behring.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating